Ziftomenib: Clinical Trials

13 trials of Ziftomenib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 recruiting, 2 active not recruiting, 1 not yet recruiting. 13 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 113Recruiting 10, Active not recruiting 2, Not yet recruiting 1
Phase 22Active not recruiting 1, Recruiting 1

Follow Ziftomenib: new trials by email Literature Review of Ziftomenib trials Research Report on Ziftomenib

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Bioavailability and Bioequivalence Study of Ziftomenib in Participants With Relapsed/Refractory AML or MDS
Ziftomenib - Myelodysplastic Syndrome (MDS)/AML, Myeloid Leukemia, Acute
Phase 1Not yet recruitingKura Oncology, Inc.1262026-10-302026-11-10
Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML
Ziftomenib, Mezigdomide - KMT2A-rearranged, NPM1-mutant Refractory or Relapsed AML
Phase 1RecruitingMassachusetts General Hospital242026-09-022026-10-08
Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia
Ziftomenib, Olutasidenib - Acute Myeloid Leukemia
Phase 1Active not recruitingM.D. Anderson Cancer Center322026-05-282026-08-24
Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia
Ziftomenib, Quizartinib - Acute Myeloid Leukemia
Phase 1RecruitingM.D. Anderson Cancer Center442025-07-102026-09-18
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
ziftomenib, imatinib mesylate - Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Stromal Cancer
Phase 1RecruitingKura Oncology, Inc.1352025-03-272026-10-27
Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
Ziftomenib, Cytarabine, Fludarabine - Relapsed/Refractory KMT2A-r Acute Leukemia, Relapsed/Refractory NUP98-r Acute Leukemia
Phase 1RecruitingPedAL BCU, LLC202025-03-182026-10-09
A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia
Venetoclax, Gemtuzumab, Ziftomenib - Acute Myeloid Leukemia
Phase 1RecruitingM.D. Anderson Cancer Center222025-03-072026-06-12
A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias
Ziftomenib, Venetoclax, Azacitidine - Refractory Acute Leukemia, Pediatric Relapsed
Phase 1RecruitingM.D. Anderson Cancer Center222024-12-272026-09-03
Ziftomenib Maintenance Post Allo-HCT
Ziftomenib - Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission
Phase 1RecruitingMassachusetts General Hospital222024-06-112026-10-06
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Ziftomenib, Fludarabine, Idarubicin - AML, AML With Mutated NPM1
Phase 1RecruitingKura Oncology, Inc.1712024-02-222026-08-20
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
Dexamethasone, Mitoxantrone, PEG asparaginase - Lymphoblastic Leukemia
Phase 1 / Phase 2RecruitingTanja Andrea Gruber902023-11-032026-11-12
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Ziftomenib, Venetoclax, Azacitidine - Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation
Phase 1RecruitingKura Oncology, Inc.4202023-07-182026-03-13
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
Ziftomenib, Midazolam, Itraconazole - Advanced Malignant Neoplasm, Acute Myeloid Leukemia
Phase 1 / Phase 2Active not recruitingKura Oncology, Inc.2632019-09-122026-05-13

Conditions studied

Leukemia, Myeloid, Acute (9)  ·  Hematologic Neoplasms (3)  ·  Leukemia (3)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (2)  ·  Recurrence (2)  ·  Gastrointestinal Stromal Tumors (1)  ·  Leukemia, Biphenotypic, Acute (1)  ·  Leukemia, Myeloid (1)  ·  Myelodysplastic Syndromes (1)  ·  Neoplasms by Histologic Type (1)  ·  Sarcoma, Myeloid (1)

Sponsors

Kura Oncology, Inc. (5)  ·  M.D. Anderson Cancer Center (4)  ·  Massachusetts General Hospital (2)  ·  PedAL BCU, LLC (1)  ·  Tanja Andrea Gruber (1)

Countries

United States (12)  ·  Canada (3)  ·  Italy (3)  ·  Spain (3)  ·  France (2)  ·  Austria (1)  ·  Belgium (1)  ·  Germany (1)  ·  Netherlands (1)

Top investigators

Amir Fathi, MD (1)  ·  Branko Cuglievan, MD (1)  ·  Courtney DiNardo, MD (1)  ·  David McCall, MD (1)  ·  Ghayas Issa, MD (1)  ·  Tanja A Gruber, MD, PhD (1)  ·  Zachariah DeFilipp, MD (1)

Results publications

PMID 33741715, PMID 34267079, PMID 39362248, PMID 40997296, PMID 41671463, PMID 42227701

NIH funding

2023 (1), 2025 (1)